Functional Imaging of Inflammatory Diseases Using Nuclear Medicine Techniques

Seminars in Nuclear Medicine

Volumn 39, Issue 2, 2009, Pages 124-145

  Basu, Sandip ^a,b   Zhuang, Hongming ^c   Torigian, Drew A ^b   Rosenbaum, Joshua ^b   Chen, Wengen ^b   Alavi, Abass ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOTACTIC PEPTIDE; CYTOKINE; FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IMMUNOGLOBULIN G; INDIUM 111; LIPOSOME; NANOCOLLOID TC 99M; OKT 3; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; DRUG UPTAKE; ENTERITIS; HUMAN; ISOTOPE LABELING; LEUKOCYTE; OSTEOARTHRITIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULITIS;

ANIMALS; CLINICAL MEDICINE; DIAGNOSTIC IMAGING; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; NUCLEAR MEDICINE; RADIOACTIVE TRACERS;

EID: 58849130730     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2008.10.006     Document Type: Review

References (138)

1. Zhuang H.M., Cortes-Blanco A., Pourdehnad M., et al. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?. Nucl Med Commun 22 (2001) 1123-1128
2. 99mTc fanolesomab). December 19, 2005. Available at: http://www.fda.gov/CDER/drug/advisory/technetium99m.htm. Accessed November 27, 2007
3. Gross M.D., Shapiro B., Fig L.M., et al. Imaging of human infection with (131)I-labeled recombinant human interleukin-8. J Nucl Med 42 (2001) 1656-1659
4. Amartey J.K., Esguerra C., Al-Otaibi B., et al. Prosthetic radioiodination of interleukin-8 ([(123/131)I]-IL-8): Biological behavior in a mouse infection model. Appl Radiat Isot 62 (2005) 39-47
5. van der Laken C.J., Boerman O.C., Oyen W.J., et al. Imaging of infection in rabbits with radioiodinated interleukin-1 (alpha and beta), its receptor antagonist and a chemotactic peptide: A comparative study. Eur J Nucl Med 25 (1998) 347-352
6. Signore A., Chianelli M., Annovazzi A., et al. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 41 (2000) 242-249
7. Moyer B.R., Vallabhajosula S., Lister-James J., et al. Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection. J Nucl Med 37 (1996) 673-679
8. Annovazzi A., Biancone L., Caviglia R., et al. 99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Chrohn's disease. Eur J Nucl Med Mol Imaging 30 (2003) 374-382
9. Diot P., Diot E., Lemarie E., et al. Imaging of pulmonary disease in scleroderma with J001X scintigraphy. Thorax 49 (1994) 504-508
10. Diot P., Le Pape A., Nolibe D., et al. Scintigraphy with J001X, a Klebsiella membrane glycolipid, for the early diagnosis of chronic berylliosis: Results from an experimental model. Br J Ind Med 49 (1992) 359-364
11. Ohtsuki K., Hayase M., Akashi K., et al. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: An autoradiographic study. Circulation 104 (2001) 203-208
12. Yu J.Q., Zhuang H., Mavi A., et al. Evaluating the role of fluorodeoxyglucose PET imaging in the management of patients with sarcoidosis. PET Clin 1 (2006) 141-152
13. Lebtahi R., Crestani B., Belmatoug N., et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 42 (2001) 21-26
14. Shorr A.F., Helman D.L., Lettieri C.J., et al. Depreotide scanning in sarcoidosis: A pilot study. Chest 126 (2004) 1337-1343
15. Hughes J.M., Rhodes C.G., Brudin L.H., et al. Contribution of the positron camera to studies of regional lung structure and function. Eur J Nucl Med 13 suppl (1987) S37-S41
16. Alavi A., Buchpiguel C.A., and Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?. J Nucl Med 35 (1994) 1650-1652
17. Larson S.M. Cancer or inflammation?. A Holy Grail for nuclear medicine. J Nucl Med 35 (1994) 1653-1655
18. Zhuang H., and Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32 (2002) 47-59
19. El-Haddad G., Zhuang H., Gupta N., et al. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 34 (2004) 313-329
20. Ishimaru S., Tsujino I., Takei T., et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26 (2005) 1538-1543
21. Xiu Y., Yu J.Q., Cheng E., et al. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med 30 (2005) 193-195
22. Nishiyama Y., Yamamoto Y., Fukunaga K., et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 47 (2006) 1571-1576
23. Brudin L.H., Valind S.O., Rhodes C.G., et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 21 (1994) 297-305
24. Milman N., Mortensen J., and Sloth C. Fluorodeoxyglucose PET scan in pulmonary sarcoidosis during treatment with inhaled and oral corticosteroids. Respiration 70 (2003) 408-413
25. Prager E., Wehrschuetz M., Bisail B., et al. Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging. Nuklearmedizin 47 (2008) 18-23
26. Teirstein A.S., Machac J., Almeida O., et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 132 (2007) 1949-1953
27. Braun J.J., Kessler R., Constantinesco A., et al. (18)F-FDG PET/CT in sarcoidosis management: Review and report of 20 cases. Eur J Nucl Med Mol Imaging (2008)
28. Hain S.F., and Beggs A.D. C-11 methionine uptake in granulomatous disease. Clin Nucl Med 29 (2004) 585-586
29. Halter G., Buck A.K., Schirrmeister H., et al. [18F] 3-deoxy-3′-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?. J Thorac Cardiovasc Surg 127 (2004) 1093-1099
30. Yamada Y., Uchida Y., Tatsumi K., et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 39 (1998) 1160-1166
31. Matoh F., Satoh H., Shiraki K., et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol 51 (2008) 179-188
32. Mana J. Nuclear imaging. 67Gallium, 201thallium, 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography. Clin Chest Med 18 (1997) 799-811
33. Okayama K., Kurata C., Tawarahara K., et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 107 (1995) 330-334
34. Okumura W., Iwasaki T., Toyama T., et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45 (2004) 1989-1998
35. Yamagishi H., Shirai N., Takagi M., et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 44 (2003) 1030-1036
36. Kaku B., Kanaya H., Horita Y., et al. Failure of follow-up gallium single-photon emission computed tomography and fluorine-18-fluorodeoxyglucose positron emission tomography to predict the deterioration of a patient with cardiac sarcoidosis. Circ J 68 (2004) 802-805
37. Sponsler J.L., Werz M.A., Maciunas R., et al. Neurosarcoidosis presenting with simple partial seizures and solitary enhancing mass: Case reports and review of the literature. Epilepsy Behav 6 (2005) 623-630
38. Ng D., Jacobs M., and Mantil J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin Nucl Med 31 (2006) 373-375
39. Aide N., Benayoun M., Kerrou K., et al. Impact of [18F]-fluorodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol 80 (2007) e67-e71
40. Kobayashi A., Shinozaki T., Shinjyo Y., et al. FDG PET in the clinical evaluation of sarcoidosis with bone lesions. Ann Nucl Med 14 (2000) 311-313
41. Ludwig V., Fordice S., Lamar R., et al. Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy. Clin Nucl Med 28 (2003) 176-179
42. Joe A., Hoegerle S., and Moser E. Cervical lymph node sarcoidosis as a pitfall in F-18 FDG positron emission tomography. Clin Nucl Med 26 (2001) 542-543
43. Lewis P.J., and Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 35 (1994) 1647-1649
44. Tannen B.L., Ghesani N.V., Frohman L., et al. Use of whole-body FDG PET-CT to aid in the diagnosis of occult sarcoidosis. Ocul Immunol Inflamm 16 (2008) 25-27
45. Yun M., Jang S., Cucchiara A., et al. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med 32 (2002) 70-76
46. Yun M., Yeh D., Araujo L.I., et al. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 26 (2001) 314-319
47. Wu Y.W., Kao H.L., Chen M.F., et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med 48 (2007) 227-233
48. Zhang Z., Machac J., Helft G., et al. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med 6 (2006) 3
49. Ogawa M., Magata Y., Kato T., et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med 47 (2006) 1845-1850
50. Rudd J.H., Myers K.S., Bansilal S., et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol 50 (2007) 892-896
51. Rudd J.H., Myers K.S., Bansilal S., et al. Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 49 (2008) 871-878
52. Tahara N., Kai H., Yamagishi S., et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 49 (2007) 1533-1539
53. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48 (2006) 1825-1831
54. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 103 (2001) 926-933
55. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104 (2001) 249-252
56. Davies J.R., Rudd J.H., Fryer T.D., et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 36 (2005) 2642-2647
57. Paulmier B., Duet M., Khayat R., et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol 15 (2008) 209-217
58. Tatsumi M., Cohade C., Nakamoto Y., et al. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: Possible finding for active atherosclerosis. Radiology 229 (2003) 831-837
59. Bural G.G., Torigian D.A., Chamroonrat W., et al. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept. Nucl Med Biol 33 (2006) 1037-1043
60. Bural G.G., Torigian D.A., Chamroonrat W., et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 35 (2008) 562-569
61. Otsuka H., Morita N., Yamashita K., et al. FDG-PET/CT for diagnosis and follow-up of vasculitis. J Med Invest 54 (2007) 345-349
62. Knockaert D.C., Vanneste L.J., and Bobbaers H.J. Fever of unknown origin in elderly patients. J Am Geriatr Soc 41 (1993) 1187-1192
63. Vanderschueren S., Knockaert D., Adriaenssens T., et al. From prolonged febrile illness to fever of unknown origin: The challenge continues. Arch Intern Med 163 (2003) 1033-1041
64. Savage C.O., Harper L., Cockwell P., et al. ABC of arterial and vascular disease: Vasculitis. Bmj 320 (2000) 1325-1328
65. Gonzalez-Gay M.A., Garcia-Porrua C., Miranda-Filloy J.A., et al. Giant cell arteritis and polymyalgia rheumatica: Pathophysiology and management. Drugs Aging 23 (2006) 627-649
66. Chong E.W., and Robertson A.J. Is temporal artery biopsy a worthwhile procedure?. ANZ J Surg 75 (2005) 388-391
67. Salvarani C., Cantini F., Boiardi L., et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (2002) 261-271
68. Blockmans D., Maes A., Stroobants S., et al. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 38 (1999) 444-447
69. Evans J.M., O'Fallon W.M., and Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122 (1995) 502-507
70. Meller J., Strutz F., Siefker U., et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 30 (2003) 730-736
71. Walter M.A., Melzer R.A., Schindler C., et al. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 32 (2005) 674-681
72. Hautzel H., Sander O., Heinzel A., et al. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: Introducing an ROC-analysis-based cutoff ratio. J Nucl Med 49 (2008) 1107-1113
73. Blockmans D., de Ceuninck L., Vanderschueren S., et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum 55 (2006) 131-137
74. Hara M., Goodman P.C., and Leder R.A. FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr 23 (1999) 16-18
75. Theron J., and Tyler J.L. Takayasu's arteritis of the aortic arch: Endovascular treatment and correlation with positron emission tomography. AJNR Am J Neuroradiol 8 (1987) 621-626
76. Webb M., Chambers A., Al-Nahhas A., et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 31 (2004) 627-634
77. Andrews J., Al-Nahhas A., Pennell D.J., et al. Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis 63 (2004) 995-1000
78. Moosig F., Czech N., Mehl C., et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: A quantitative PET study. Ann Rheum Dis 63 (2004) 870-873
79. Marienhagen J., Geissler A., and Lang B. High resolution single photon emission computed tomography of the brain in Wegener's granulomatosis. J Rheumatol 23 (1996) 1828-1830
80. Wildhagen K., Stoppe G., Meyer G.J., et al. [Imaging diagnosis of central nervous system involvement in panarteritis nodosa]. Z Rheumatol 48 (1989) 323-325
81. van Dam A.P. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 11 (1991) 1-11
82. Stoppe G., Wildhagen K., Seidel J.W., et al. Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology 40 (1990) 304-308
83. Sailer M., Burchert W., Ehrenheim C., et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 244 (1997) 186-193
84. Weiner S.M., Otte A., Schumacher M., et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: Value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 59 (2000) 377-385
85. Gratz S., Rennen H.J., Boerman O.C., et al. Rapid imaging of experimental colitis with (99m)Tc-interleukin-8 in rabbits. J Nucl Med 42 (2001) 917-923
86. Basu S., Torigian D., and Alavi A. The role of modern molecular imaging techniques in gastroenterology. Gastroenterology 135 (2008) 1055-1061
87. Shreve P.D., Anzai Y., and Wahl R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics 19 (1999) 61-77 quiz 150-151
88. Pio B.S., Byrne F.R., Aranda R., et al. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells. Mol Imaging Biol 5 (2003) 271-277
89. Miraldi F., Vesselle H., Faulhaber P.F., et al. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 23 (1998) 3-7
90. Lemberg D.A., Issenman R.M., Cawdron R., et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 733-738
91. Loffler M., Weckesser M., Franzius C., et al. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 1072 (2006) 379-385
92. Neurath M.F., Vehling D., Schunk K., et al. Noninvasive assessment of Crohn's disease activity: A comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97 (2002) 1978-1985
93. Meisner R.S., Spier B.J., Einarsson S., et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 13 (2007) 993-1000
94. Louis E., Ancion G., Colard A., et al. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med 48 (2007) 1053-1059
95. Bostel F., and Hauger W. 99mTc-nanocolloid: Clinical results of its use as a new inflammation marker. [in German]. Rofo 149 (1988) 648-653
96. Vorne M., Lantto T., Paakkinen S., et al. Clinical comparison of 99Tcm-HMPAO labelled leucocytes and 99Tcm-nanocolloid in the detection of inflammation. Acta Radiol 30 (1989) 633-637
97. Makela A.L., Soini I., and Makela P. Technetium-99m nanocolloid scintigraphy in rheumatic inflammation in children. Acta Univ Carol [Med] (Praha) 37 (1991) 61-67
98. Ang E.S., Sundram F.X., Goh A.S., et al. 99Tcm-polyclonal IgG and 99Tcm nanocolloid scans in orthopaedics: A comparison with conventional bone scan. Nucl Med Commun 14 (1993) 419-432
99. Palosaari K., Vuotila J., Takalo R., et al. Contrast-enhanced dynamic and static MRI correlates with quantitative 99Tcm-labelled nanocolloid scintigraphy. Study of early rheumatoid arthritis patients. Rheumatology (Oxford) 43 (2004) 1364-1373
100. Breedveld F.C., van Kroonenburgh M.J., Camps J.A., et al. Imaging of inflammatory arthritis with technetium-99m-labeled IgG. J Nucl Med 30 (1989) 2017-2021
101. Wandler E., Kramer E.L., Sherman O., et al. Diffuse FDG shoulder uptake on PET is associated with clinical findings of osteoarthritis. AJR Am J Roentgenol 185 (2005) 797-803
102. Zhuang H., Chacko T.K., Hickeson M., et al. Persistent non-specific FDG uptake on PET imaging following hip arthroplasty. Eur J Nucl Med Mol Imaging 29 (2002) 1328-1333
103. Zhuang H., Sam J.W., Chacko T.K., et al. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur J Nucl Med Mol Imaging 30 (2003) 1096-1103
104. Polisson R.P., Schoenberg O.I., Fischman A., et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 819-825
105. Ju JH, Kang KY, Kim IJ, et al: Visualization and localization of rheumatoid knee synovitis with FDG-PET/CT images. Clin Rheumatol (in press)
106. Vogel W.V., van Riel P.L., and Oyen W.J. FDG-PET/CT can visualise the extent of inflammation in rheumatoid arthritis of the tarsus. Eur J Nucl Med Mol Imaging 34 (2007) 439
107. Parsons M., Torigian D., and Alavi A. Metabolic activity in the painful knee joint as measured on FDG-PET. J Nucl Med 49 (2008) 270P
108. El-Haddad G., Kumar R., Pamplona R., et al. PET/MRI depicts the exact location of meniscal tear associated with synovitis. Eur J Nucl Med Mol Imaging 33 (2006) 507-508
109. Basu S., Chryssikos T., Houseni M., et al. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection?. Nucl Med Commun 28 (2007) 465-472
110. Houseni M., Chamroonrat W., Zhuang H., et al. Facet joint arthropathy demonstrated on FDG-PET. Clin Nucl Med 31 (2006) 418-419
111. Knockaert D.C., Vanneste L.J., Vanneste S.B., et al. Fever of unknown origin in the 1980s. An update of the diagnostic spectrum. Arch Intern Med 152 (1992) 51-55
112. de Kleijn E.M., Vandenbroucke J.P., and van der Meer J.W. Fever of unknown origin (FUO). I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria The Netherlands FUO Study Group. Medicine (Baltimore) 76 (1997) 392-400
113. Kazanjian P.H. Fever of unknown origin: Review of 86 patients treated in community hospitals. Clin Infect Dis 15 (1992) 968-973
114. Hirschmann J.V. Fever of unknown origin in adults. Clin Infect Dis 24 (1997) 291-300 quiz 301-292
115. Cunha B.A. Fever of unknown origin. Infect Dis Clin North Am 10 (1996) 111-127
116. Jones H.A., Marino P.S., Shakur B.H., et al. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 21 (2003) 567-573
117. Kicska G., Zhuang H., and Alavi A. Acute bronchitis imaged with F-18 FDG positron emission tomography. Clin Nucl Med 28 (2003) 511-512
118. Chen D.L., and Schuster D.P. Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am J Physiol Lung Cell Mol Physiol 286 (2004) L834-L840
119. Alavi A., Gupta N., Alberini J.L., et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 32 (2002) 293-321
120. Lin E.C., and Quaife R.A. FDG uptake in chronic superior vena cava thrombus on positron emission tomographic imaging. Clin Nucl Med 26 (2001) 241-242
121. Raman S., Nunez R., Oliver Wong C., et al. F-18 FDG positron emission tomographic image of an aortic aneurysmal thrombus. Clin Nucl Med 27 (2002) 213-214
122. Bhargava P., Kumar R., Zhuang H., et al. Catheter-related focal FDG activity on whole body PET imaging. Clin Nucl Med 29 (2004) 238-242
123. Chang K.J., Zhuang H., and Alavi A. Detection of chronic recurrent lower extremity deep venous thrombosis on fluorine-18 fluorodeoxyglucose positron emission tomography. Clin Nucl Med 25 (2000) 838-839
124. Mathew A.S., El-Haddad G., Lilien D.L., et al. Costosternal chondrodynia simulating recurrent breast cancer unveiled by FDG PET. Clin Nucl Med 33 (2008) 330-332
125. Shih W.J., Ghesani N., Hongming Z., et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: Before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 27 (2002) 142-143
126. Belakhlef A., Jani C., Church C., et al. Fat necrosis mimicking B-cell lymphoma: A PET/CT and FDG study. Clin Nucl Med 33 (2008) 271-272
127. Yu J.Q., Zhuang H., Xiu Y., et al. Demonstration of increased FDG activity in Rosai-Dorfman disease on positron emission tomography. Clin Nucl Med 29 (2004) 209-210
128. Nakajo M., Jinnouchi S., Noguchi M., et al. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. Clin Nucl Med 32 (2007) 282-285
129. Serizawa I., Inubushi M., Kanegae K., et al. Lymphadenopathy due to amyloidosis secondary to Sjogren syndrome and systemic lupus erythematosus detected by F-18 FDG PET. Clin Nucl Med 32 (2007) 881-882
130. Yu J.Q., Milestone B.N., Parsons R.B., et al. Findings of intramediastinal gossypiboma with F-18 FDG PET in a melanoma patient. Clin Nucl Med 33 (2008) 344-345
131. Niederkohr R.D., Hwang B.J., and Quon A. FDG PET/CT detection of a gossypiboma in the neck. Clin Nucl Med 32 (2007) 893-895
132. Hayasaka K., Nihashi T., Takebayashi S., et al. FDG PET in Lhermitte-Duclos disease. Clin Nucl Med 33 (2008) 52-54
133. Repko B.M., and Tulchinsky M. Increased F-18 FDG uptake in resolving atraumatic bilateral adrenal hemorrhage (hematoma) on PET/CT. Clin Nucl Med 33 (2008) 651-653
134. Bagga S. Baker cyst as seen on a PET/CT scan. Clin Nucl Med 33 (2008) 64-65
135. Post M.C., Grutters J.C., Verzijlbergen J.F., et al. PET scintigraphy of etoposide-induced pulmonary toxicity. Clin Nucl Med 32 (2007) 683-684
136. Basu S., and Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: Detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 10 (2008) 131-137
137. Pellegrino D., Bonab A.A., Dragotakes S.C., et al. Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med 46 (2005) 1522-1530
138. Radu C.G., Shu C.J., Nair-Gill E., et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2′-deoxycytidine analog. Nat Med 14 (2008) 783-788